EXEL - Exelixis, Inc.
| Previous Close | 20.830 |
| Open | 20.860 |
| Bid | 21.150 x 100 |
| Ask | 21.180 x 1400 |
| Day's Range | 20.690 - 21.240 |
| 52 Week Range | 18.030 - 32.500 |
| Volume | 367,200 |
| Avg. Volume | 3,059,345 |
| Market Cap | 6.237B |
| Beta | 2.21 |
| PE Ratio (TTM) | 42.65 |
| EPS (TTM) | 0.493 |
| Earnings Date | May 2, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.00 |
- Business Wire•2 hours ago
Cabozantinib to Be Featured in 15 Presentations at ASCO 2018 Annual Meeting
Exelixis, Inc. today announced that data from clinical trials of cabozantinib will be the subject of 15 presentations at the American Society of Clinical Oncology 2018 Annual Meeting in Chicago, June 1-5, 2018.
- Market Realist•7 days ago
Analysts’ Recommendations for Exelixis in April 2018
In February 2018, Exelixis (EXEL) and its partner Daiichi Sankyo announced that it had submitted a regulatory application for esaxerenone therapy to the Japanese Pharmaceutical and Medical Devices Agency for the treatment of individuals with hypertension. According to the prior agreement between Exelixis and Daiichi Sankyo, Exelixis is set to receive a milestone payment of $20 million from Daiichi Sankyo. Daiichi Sankyo’s regulatory application has been supported by the results of Phase 3 trials evaluating the safety and efficacy of esaxerenone in individuals with essential hypertension compared to eplerenone.
- Market Realist•7 days ago
Cabometyx Could Be Exelixis’s Long-Term Growth Driver
In March 2018, the FDA accepted Exelixis’s (EXEL) supplemental New Drug Application (or sNDA) for Cabometyx as a therapy for the treatment of individuals with advanced hepatocellular carcinoma (or HCC) who have previously undergone therapy. Exelixis’s sNDA was based on the results of its Phase 3 CELESTIAL trial. In October 2017, an independent data-monitoring committee recommended that Exelixis stop its CELESTIAL efficacy trial after a review of the second planned interim analysis, wherein Cabometyx demonstrated statistically significant and clinically meaningful progress in overall survival compared to the placebo in individuals who had already been treated for advanced HCC.
Market Realist•8 days agoHow Exelixis’s Cabomeytx and Cometriq Performed in 4Q17 and 2017
In 4Q17, Exelixis’s (EXEL) Cabometyx reported revenue of $90.4 million compared to $44.7 million in 4Q16, which reflected a ~102% rise on a YoY (year-over-year) basis. The FDA’s approval of the drug’s label expansion also boosted its revenue growth in 4Q17. In 2017, Cabometyx generated revenue of $324 million compared to $93.5 million in 2016.
Market Realist•8 days agoWhat to Expect from Exelixis in 1Q18
In 4Q17, Exelixis (EXEL) generated revenue of $115.9 million compared to $75.7 million in 4Q16, which reflected a ~55% rise on a year-over-year (or YoY) basis and a ~19% fall on a quarter-over-quarter basis. In 4Q17, Exelixis generated revenue of $95.7 million from net product sales and $24.4 million from collaborations. In 4Q17, Cabometyx primarily pushed this revenue growth.
- Investopedia•8 days ago
Why Big Biotech Stocks May Get An Earnings Boost
Big Bounce: Big biotech stocks may surge on better-than-expected quarterly results
Markit•9 days agoSee what the IHS Markit Score report has to say about Exelixis Inc.
Exelixis Inc NASDAQ/NGS:EXEL
- GlobeNewswire•9 days ago
New Research Coverage Highlights Exelixis, Verizon Communications, AT&T, Snap, Allergan plc, and QUALCOMM — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, April 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Motley Fool•14 days ago
Why Exelixis' Stock Broke Down in March
Exelixis' shares continue to revert to the mean. Is the bottom near?
- Business Wire•15 days ago
Exelixis to Release First Quarter 2018 Financial Results on Wednesday, May 2, 2018
Exelixis, Inc. announced today that its first quarter 2018 financial results will be released on Wednesday, May 2, 2018 after the markets close. At 5:00 p.m. EDT / 2:00 p.m.
- Zacks•15 days ago
Exelixis (EXEL) in Focus: Stock Moves 7.7% Higher
Exelixis (EXEL) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
- Investor's Business Daily•16 days ago
Exelixis Rebounds As Analyst Urges Investors To Buy Monday's Dip
Exelixis shares rebounded Tuesday from a 10-month low at Monday's close after regulators temporarily halted enrollment in a cancer study combining drugs from Exelixis and Roche.
- ACCESSWIRE•16 days ago
Today’s Research Reports on Trending Tickers: Exact Sciences and Exelixis
NEW YORK, NY / ACCESSWIRE / April 10, 2018 / U.S. markets rallied in early trading Monday on the strength of technology stocks and the easing of trade relations between the U.S. and China. However, most ...
- Business Wire•17 days ago
Exelixis Elects Dr. Maria Freire to Its Board of Directors
Exelixis, Inc. today announced that renowned biomedical research executive Maria C. Freire, Ph.D. has been elected to the company’s Board of Directors. Dr. Freire’s appointment took effect on April 5, 2018.
- Zacks•20 days ago
Moving Average Crossover Alert: Exelixis, Inc. (EXEL)
Moving Average Crossover Alert: Exelixis, Inc. (EXEL)
- ACCESSWIRE•21 days ago
Today’s Research Reports on Trending Tickers: Exelixis and Galectin Therapeutics
NEW YORK, NY / ACCESSWIRE / April 5, 2018 / After falling sharply on global trade fears in early trading Wednesday, U.S. stocks rallied to close in the green. The Dow Jones Industrial Average touched a ...
- Motley Fool•22 days ago
3 Top Biotech Stocks to Buy in April
Biotech stocks are falling, and that could be creating an opportunity to buy shares in these top companies.
- Investor's Business Daily•22 days ago
Why Exelixis Will Triumph In Liver Cancer Battle With Eli Lilly
A battle brewing in liver cancer will land Exelixis on top, an analyst said Wednesday after rival Eli Lilly posted strong topline results for its drug.
- Investopedia•22 days ago
Top 5 Biotech Stocks for 2018
Biotech can be risky, but these top biotech stocks have stable track records.
- Zacks•22 days ago
Weakness Seen in Exelixis (EXEL) Estimates: Should You Stay Away?
Exelixis (EXEL) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.
- Market Realist•23 days ago
Why Spark Therapeutics Stock Rose in the Week Ended March 29
A Look at Pharma's Gainers in the Week Ended March 29
- ACCESSWIRE•24 days ago
Wired News – Exelixis’ Partner Ipsen Gets EMA Validation of the Application for a New Indication for CABOMETYX
Stock Monitor: ChemoCentryx Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 02, 2018 / Active-Investors.com has just released a free research report on Exelixis, Inc. (NASDAQ: EXEL ). If you want ...
- ACCESSWIRE•28 days ago
Today’s Research Reports on Trending Tickers: Exelixis and Sarepta Therapeutics
NEW YORK, NY / ACCESSWIRE / March 29, 2018 / U.S. markets fell for the second consecutive session Wednesday as the tech sector’s struggles continued. The Dow Jones Industrial Average declined 0.04 percent ...
- Zacks•29 days ago
Why Is Exelixis (EXEL) Down 17.2% Since Its Last Earnings Report?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire•29 days ago
Exelixis’ Partner Ipsen Announces EMA Validation of the Application for a New Indication for CABOMETYX® (cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma
Exelixis, Inc. today announced that its partner Ipsen received validation of the application for variation to the CABOMETYX® marketing authorization from the European Medicines Agency , the European regulatory authority, for the addition of a new indication for patients with previously treated advanced hepatocellular carcinoma .
